Key Takeaways Veeva Systems added 28 Vault CRM customers in Q1 FY26, reaching 80 total live deployments. Three of the top 20 global biopharma firms have adopted Veeva Systems' Vault CRM suite. Veeva Systems' CRM Pulse and upcoming AI features aim to deepen platform capabilities by the end of 2025.Veeva Systems (VEEV) is seeing strong momentum in its next-gen Vault CRM (customer relationship management) offering, with fiscal first-quarter 2026 results highlighting rapid customer adoption and strategic posi ...

Core Insights - Veeva Systems (VEEV) is strategically expanding its partnerships in 2025, enhancing its integration within the life sciences sector and driving growth [1][3][7] Partnerships and Collaborations - In June 2025, Veeva partnered with the Sarah Cannon Research Institute to implement its Clinical Platform at over 200 oncology research sites, validating its technology for cancer trials [1] - Astellas selected Veeva's Vault CRM as its global standard for commercial operations, including a version tailored for China [1] - Veeva collaborated with Zifo in January 2025 to facilitate the integration of lab quality data into Veeva LIMS, expediting system rollouts [1] - EVERSANA joined Veeva's partner program in April 2025 to co-develop generative AI tools for content creation and customer engagement [2] - Partnerships with DNAnexus and Accumulus Synergy have enhanced Veeva's regulatory capabilities, aiding pharma companies in managing global filings [2] Market Position and Performance - Veeva's partnerships are accelerating adoption, strengthening customer relationships, and creating new growth avenues in clinical research, AI engagement, and regulatory compliance [3] - VEEV shares have increased by 33.5% year-to-date, significantly outperforming the industry growth of 8.1% [6][7] Valuation and Earnings Estimates - Veeva trades at a forward price-to-sales ratio of 14.25, which is above the industry average [8] - The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings suggests a 15.8% increase compared to the previous year [9] - Current earnings estimates for the upcoming quarters indicate a year-over-year growth of 17.28% for the current quarter and 15.76% for the current year [10]